Who are Celontin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Succitimal, Paradione, Horizant, OXCARBAZEPINE, Gabitril, Cerebyx.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methsuximide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Celontin — Competitive Intelligence Brief

Celontin (METHSUXIMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-epileptic Agent. Area: Neuroscience.

marketed Anti-epileptic Agent Voltage-gated T-type calcium channel Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Celontin (METHSUXIMIDE) — Pfizer. Celontin works by blocking the activity of voltage-gated T-type calcium channels in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Celontin TARGET	METHSUXIMIDE	Pfizer	marketed	Anti-epileptic Agent	Voltage-gated T-type calcium channel	1957-01-01
Succitimal	PHENSUXIMIDE		marketed	phensuximide	Voltage-gated T-type calcium channel	1982-01-01
Paradione	PARAMETHADIONE		marketed	paramethadione	Voltage-gated T-type calcium channel	1949-01-01
Horizant	GABAPENTIN ENACARBIL	Azurity	marketed	Anti-epileptic Agent	Voltage-dependent calcium channel subunit alpha-2/delta-1	2011-01-01
OXCARBAZEPINE	OXCARBAZEPINE		marketed	Anti-epileptic Agent [EPC]		2000-01-01
Gabitril	TIAGABINE	Cephalon	marketed	Anti-epileptic Agent	Sodium- and chloride-dependent GABA transporter 1	1997-01-01
Cerebyx	FOSPHENYTOIN	Pfizer	marketed	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-epileptic Agent class)

Pfizer · 2 drugs in this class
Azurity · 1 drug in this class
Cephalon · 1 drug in this class
Novartis · 1 drug in this class
Recordati · 1 drug in this class
Viatris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celontin — Competitive Intelligence Brief. https://druglandscape.com/ci/methsuximide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab